furanodienone: an antineoplastic agent that suppresses estrogen receptor alpha (ERalpha) signaling; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6506548 |
| CHEBI ID | 182399 |
| CHEBI ID | 80825 |
| SCHEMBL ID | 24422157 |
| MeSH ID | M0559158 |
| Synonym |
|---|
| furanodienone |
| CHEBI:182399 |
| (5e,9e)-3,6,10-trimethyl-8,11-dihydro-7h-cyclodeca[b]uran-4-one |
| (5e,9e)-3,6,10-trimethyl-8,11-dihydro-7h-cyclodeca[b]furan-4-one |
| C16960 |
| 24268-41-5 |
| dh78skj88k , |
| germacra-1(10),4,7,11-tetraen-6-one, 8,12-epoxy-, (e,e)- |
| CHEBI:80825 |
| AC-34214 |
| (5e,9e)-3,6,10-trimethyl-7,8-dihydrocyclodeca[b]furan-4(11h)-one |
| cyclodeca[b]furan-4(7h)-one, 8,11-dihydro-3,6,10-trimethyl-, (e,e)- |
| (1(10)e,4e)-8,12-epoxygermacra-1(10),4,7,11-tetraen-6-one |
| XVOHELPNOXGRBQ-NXAIOARDSA-N |
| cyclodeca[b]furan-4(7h)-one, 8,11-dihydro-3,6,10-trimethyl-, (5e,9e)- |
| AKOS032946002 |
| DTXSID801019961 |
| (5e,9e)-3,6,10-trimethyl-8,11-dihydrocyclodeca[b]furan-4(7h)-one |
| CS-0019492 |
| HY-N2184 |
| MS-23311 |
| SCHEMBL24422157 |
| cyclodeca(b)furan-4(7h)-one, 8,11-dihydro-3,6,10-trimethyl-, (e,e)- |
| cyclodeca(b)furan-4(7h)-one, 8,11-dihydro-3,6,10-trimethyl-, (5e,9e)- |
| (5e,9e)-8,11-dihydro-3,6,10-trimethylcyclodeca(b)furan-4(7h)-one |
| HY-N10840 |
| CS-0637047 |
| furanogermacra-1(10)z,4z-dien-6-one |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Furanodienone treatment inhibited E2-stimulation of estrogen response element (ERE)-driven reporter plasmid activity and ablated E2-targeted gene (e.g., c-Myc, Bcl-2, and cyclin D1) expression which resulted in the inhibition of cell cycle progression and cell proliferation, and in the induction of apoptosis." | ( Furanodienone inhibits cell proliferation and survival by suppressing ERĪ± signaling in human breast cancer MCF-7 cells. Chu, JH; Fong, WF; Li, YW; Shen, XL; Yu, ZL; Zhu, GY, 2011) | 2.53 |
| Class | Description |
|---|---|
| germacrane sesquiterpenoid | Any sesquiterpenoid having a germacrane skeleton. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.86) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||